Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature

Journal of Ocular Pharmacology and Therapeutics

Volumn 31, Issue 10, 2015, Pages 605-610

  Polizzi, Silvio ^a   Mahajan, Vinit B ^b,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ABSENCE OF SIDE EFFECTS; ADULT; ASSISTED VENTILATION; BRADYCARDIA; BRAIN HEMORRHAGE; CASE REPORT; CESAREAN SECTION; CHILD DEVELOPMENT; CONCEPTION; FEMALE; GESTATION PERIOD; HUMAN; LUNG HEMORRHAGE; NEONATAL RESPIRATORY DISTRESS SYNDROME; OCULAR HISTOPLASMOSIS; OXYGEN THERAPY; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PULMONARY VALVE STENOSIS; RESPIRATORY FAILURE; RESPIRATORY TRACT INTUBATION; REVIEW; RISK FACTOR; SPONTANEOUS ABORTION; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; THIRD TRIMESTER PREGNANCY; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; NEWBORN; PREGNANCY COMPLICATIONS;

ADULT; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; FEMALE; HUMANS; INFANT, NEWBORN; INTRAVITREAL INJECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84973392505     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2015.0056     Document Type: Review

References (62)

1. Chan, W.M., Lai, T.Y., Liu, D.T., and Lam, D.S. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology. 114:2190-2196, 2007
2. Traversi, C., Nuti, E., Marigliani, D., Cevenini, G., et al. Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 253:511-517, 2015
3. Mandal, S., Garg, S., Venkatesh, P., Mithal, C., Vohra, R., and Mehrotra, A. Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization. Arch. Ophthalmol. 125:1487-1492, 2007
4. Kim, H., Lee, K., Lee, C.S., Byeon, S.H., and Lee, S.C. Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy. Retina. 35:481-486, 2015
5. Rosina, C., Romano, M., Cigada, M., Polo, L.D., Staurenghi, G., and Bottoni, F. Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks: a long-term follow-up study. Eur. J. Ophthalmol. 25:47-50, 2015
6. Battaglia Parodi, M., Iacono, P., La Spina, C., et al. Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks. Am. J. Ophthalmol. 157:374-377, 2014
7. Adan, A., Mateo, C., Navarro, R., Bitrian, E., and Casaroli-Marano, R.P. Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina. 27:1180-1186, 2007
8. Chan, W.M., Lai, T.Y., Liu, D.T., and Lam, D.S. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am. J. Ophthalmol. 143:977-983, 2007
9. Schadlu, R., Blinder, K.J., Shah, G.K., et al. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am. J. Ophthalmol. 145:875-878, 2008
10. Battaglia Parodi, M., De Benedetto, U., Knutsson, K.A., et al. Juxtafoveal choroidal neovascularization associated with retinitis pigmentosa treated with intravitreal bevacizumab. J. Ocul. Pharmacol. Ther. 28:202-204, 2012
11. Parodi, M.B., Iacono, P., Cascavilla, M., Zucchiatti, I., Kontadakis, D.S., and Bandello, F. Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy. Invest. Ophthalmol. Vis. Sci. 51:4358-4361, 2010
12. Ahmadieh, H., and Vafi, N. Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab (Avastin). Graefes Arch. Clin. Exp. Ophthalmol. 245:1731-1733, 2007
13. Song, W.K., Koh, H.J., Kwon, O.W., Byeon, S.H., and Lee, S.C. Intravitreal bevacizumab for choroidal neovascularization secondary to choroidal osteoma. Acta Ophthalmol. 87:100-101, 2009
14. Cordero Coma, M., Sobrin, L., Onal, S., Christen, W., and Foster, C.S. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology. 114:1574-1579, 2007
15. Ziemssen, F., Deuter, C.M., Stuebiger, N., and Zierhut, M. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch. Clin. Exp. Ophthalmol. 245:917-918, 2007
16. Weiss, K., Steinbrugger, I., Weger, M., et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye (Lond). 23:1812-1818, 2009
17. Arcieri, E.S., Paula, J.S., Jorge, R., et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmol. 93:e1-e6, 2015
18. Avery, R.L., Pearlman, J., Pieramici, D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 113:1695, e1-e15, 2006
19. Rizzo, S., Genovesi-Ebert, F., Di Bartolo, E., Vento, A., Miniaci, S., and Williams, G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch. Clin. Exp. Ophthalmol. 246:837-842, 2008
20. Sinawat, S., Rattanapakorn, T., Sanguansak, T., et al. Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation. Eye (Lond). 27:1391-1396, 2013
21. Kook, D., Wolf, A., Kreutzer, T., et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabeticmacular edema. Retina. 28:1053-1060, 2008
22. Almawi, W.Y., Saldanha, F.L., Mahmood, N.A., Al-Zaman, I., Sater, M.S., and Mustafa, F.E. Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage. Hum. Reprod. 28:2628-2635, 2013
23. Ferrara, N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 280:C1358-C1366, 2001
24. Galazios, G., Papazoglou, D., Tsikouras, P., and Kolios, G. Vascular endothelial growth factor gene polymorphisms and pregnancy. J. Matern. Fetal Neonatal. Med. 22:371-378, 2009
25. Granger, J.P. Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors? Hypertension. 54:465-467, 2009
26. Sane,D.C., Anton, L., and Brosnihan, K.B. Angiogenic growth factors and hypertension. Angiogenesis. 7:193-201, 2004
27. Cross, S.N., Ratner, E., Rutherford, T.J., Schwartz, P.E., and Norwitz, E.R. Bevacizumab-mediated interference with VEGF signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women. Rev. Obstet. Gynecol. 5:2-8, 2012
28. Raiser, R., Artunay, O., Yuzbasioglu, E., Senegal, A., and Behcecioglu, H. The effect of intravitreal bevacizumab (Avastin) administration on systemic hypertension. Eye. 23:1714-1718, 2009
29. Kubota, T., Kiuchi, Y., and Sheridan, C. Anti-vascular endothelial growth factor agents for ocular angiogenesis and vascular permeability. J. Ophthalmol. 2012:898207, 2012
30. Avery, R.L., Castellarin, A.A., Steinle, N.C., et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br. J. Ophthalmol. 98:1636-1641, 2014
31. Gu, X., Yu, X., and Dai, H. Intravitreal injection of ranibizumab for treatment of age-relatedmacular degeneration: effects on serum VEGF concentration. Curr. Eye Res. 39:518-521, 2014
32. Zehetner, C., Kirchmair, R., Huber, S., Kralinger, M.T., and Kieselbach,G.F. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br. J. Ophthalmol. 97:454-459, 2013
33. Matsuyama, K., Ogata, N., Matsuoka, M., Wada, M., Takahashi, K., and Nishimura, T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br. J. Ophthalmol. 94:1215-1218, 2010
34. Rosen, E., Rubowitz, A., and Ferencz, J.R. Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy. Eye (Lond). 23:1479, 2009
35. Wu, Z., Huang, J., and Sadda, S. Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report. Ann. Acad. Med. Singapore. 39:143, 2010
36. Petrou, P., Georgalas, I., Giavaras, G., Anastasiou, E., Ntana, Z., and Petrou, C. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol. 88:e136, 2010
37. Tarantola, R.M., Folk, J.C., Boldt, H.C., and Mahajan, V.B. Intravitreal bevacizumab during pregnancy. Retina. 30:1405-1411, 2010
38. Sarhianaki, A., Katsimpris, A., Petropoulos, I.K., Livieratou, A., Theoulakis, P.E., and Katsimpris, J.M. Intravitreal administration of ranibizumab for idiopathic choroidal neovascularization in a pregnant woman. Klin Monatsbl Augenheilkd. 229:451-453, 2012
39. Introini, U., Casalino, G., Cardani, A., Scotti, F., Finardi, A., Candiani, M., et al. Intravitreal bevacizumab for a subfoveal myopic choroidal neovascularization in the first trimester of pregnancy. J. Ocul. Pharmacol. Ther. 28:553-555, 2012
40. Gomez Ledesma I, Santiago Rodriguez MA , Follana Neira I, and Leon Garrigosa F. Neovascular membrane and pregnancy. Treatment with bevacizumab. Arch Soc. Esp. Oftalmol. 88:453-454, 2013
41. Sullivan, L., Kelly, S.P., Glenn, A., Williams, C.P., and McKibbin, M. Intravitreal bevacizumab injection in unrecognised early pregnancy. Eye (Lond). 28:492-494, 2014
42. Polizzi, S., Ferrara, G., Restaino, S., Rinaldi, S., and Tognetto, D. Inadvertent use of bevacizumab in pregnant women with diabetes mellitus type. J. Basic Clin. Physiol. Pharmacol. 26:161-163, 2015
43. Jouve, L., Akesbi, J., and Nordmann, J.P. Safety and efficacy of ranibizumab for pregnant women in idiopathic choroidal neovascularization. Acta Ophthalmol. 2014 [Epub ahead of print]; DOI: 10.1111/aos.12611
44. Ford, H.B., and Schust, D.J. Recurrent pregnancy loss: etiology, diagnosis, and therapy. Rev. Obstet. Gynecol. 2:76-83, 2009
45. Everett, C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ. 315:32-34, 1997
46. Huisjes, H.J. Spontaneous Abortion. London: Churchill Livingstone; 1984; p. 6
47. Knudsen, U.B., Hansen, V., Juul, S., and Secher, N.J. Prognosis of a new pregnancy following previous spontaneous abortions. Eur. J. Obstet. Gynecol. Reprod. Biol. 39:31-36, 1991
48. Stabile, I., Grudzinskas, G., and Chard, T. Spontaneous Abortion. London: Springer-Verlag; 1992
49. Regan, L., Braude, P.R., and Trembath, P.L. Influence of past reproductive performance on risk of spontaneous abortion. BMJ. 299:541-545, 1989
50. Warburton, D., and Fraser, F.C. Spontaneous abortion risks in man: data from reproductive histories collected in a medical genetics unit. Hum. Genet. 16:1-25, 1964
51. Petersson, F. Epidemiology of Early Pregitancvs Wastage. Stockholm: Svenska Bokforlaget; 1968
52. Poland, B.J., Miller, J.R., Jones, D.C., and Trimble, B.K. Reproductive counselling in patients who have had a spontaneous abortion. Am. J. Obstet. Gynecol. 127:685-691, 1977
53. Whittaker, P.G., Taylor, A., and Lind, T. Unsuspected pregnancy loss in healthy women. Lancet. 1:1126-1127, 1983
54. Wilcox, A.J., Weinberg, C.R., O'Connor, J.F., Baird, D.D., Schlatterer, J.P., Canfield, R.E., Armstrong, E.G., and Nisula, B.C. Incidence of early loss of pregnancy. N. Engl. J. Med. 319:189-194, 1988
55. Oakley, A., McPherson, A., and Roberts, H. Miscarriage. London: Fontana; 1984
56. Korkes, H.A., Sass, N., Moron, A.F., Camara, N.O., Bonetti, T., Cerdeira, A.S., Da Silva, I.D., and De Oliveira, L. Lipidomic assessment of plasma and placenta of women with early-onset preeclampsia. PLoSOne. 9:e110747, 2014
57. Rana, S., Cerdeira, A.S., Wenger, J., Salahuddin, S., Lim, K.H., et al. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One. 7:e48259, 2012
58. Turner, J.A. Diagnosis and management of pre-eclampsia: an update. Int. J. Womens Health. 2:327-337, 2010
59. Oliveira, L.G., Karumanchi, A., and Sass, N. Preeclampsia: oxidative stress, inflammation and endothelial dysfunction. Rev. Bras. Ginecol. Obstet. 32:609-616, 2010
60. ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int. J. Gynaecol. Obstet. 77:67-75, 2002
61. Brandt, M.T., and Haug, R. Traumatic hyphema: a comprehensive review. J. Oral Maxillofac. Surg. 59:1462-1470, 2001
62. Sadler, T.W. Susceptible periods during embryogenesis of the heart and endocrine glands. Environ. Health Perspect. 108 Suppl 3:555-561, 2000